Nilotinib after imatinib first‐line: a real‐life longitudinal cohort of patients with chronic myeloid leukaemia in chronic phase

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 3, 2018-02 ,pp. : 356-364

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real‐life data from PSONET registries

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 32, Iss. 2, 2018-02 ,pp. : 245-253

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two‐year persistence of golimumab as second‐line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real‐life data from the LORHEN registry

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 2, 2018-02 ,pp. : 422-430

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 12, 2015-12 ,pp. : 2349-2355

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 12, 2015-12 ,pp. : 2411-2416

John Wiley & Sons Inc

Access to resources Recommend Favorite